Moomoo AI 已提取核心訊息
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
全球生物製藥公司艾伯維公司宣佈發行150億美元的優先票據，期限從2027年到2064年不等。此次發行包括2027年到期的22.5億美元4.800％的優先票據，2029年到期的25億美元4.800％優先票據，2031年到期的4.950％優先票據，2034年到期的30億美元5.050％優先票據，2044年到期的7.5億美元5.400％優先票據，2054年到期的30億美元5.500％優先票據，以及2064年到期的15億美元5.500％優先票據。從2024年9月15日起，每系列票據的利息每半年支付一次。該公司計劃將出售票據的淨收益用於各種公司用途，包括償還新定期融資機制下的貸款、爲Cerevel合併對價提供資金、償還公司商業票據計劃下的未償借款、支付相關費用和開支以及一般公司用途。這些票據由摩根士丹利、摩根大通、美銀證券和花旗集團牽頭的一組承銷商發行，其他幾家金融機構則以聯席賬面管理人和聯席經理的身份參與。此次發行預計將於2024年2月26日結束。
全球生物製藥公司艾伯維公司宣佈發行150億美元的優先票據，期限從2027年到2064年不等。此次發行包括2027年到期的22.5億美元4.800％的優先票據，2029年到期的25億美元4.800％優先票據，2031年到期的4.950％優先票據，2034年到期的30億美元5.050％優先票據，2044年到期的7.5億美元5.400％優先票據，2054年到期的30億美元5.500％優先票據，以及2064年到期的15億美元5.500％優先票據。從2024年9月15日起，每系列票據的利息每半年支付一次。該公司計劃將出售票據的淨收益用於各種公司用途，包括償還新定期融資機制下的貸款、爲Cerevel合併對價提供資金、償還公司商業票據計劃下的未償借款、支付相關費用和開支以及一般公司用途。這些票據由摩根士丹利、摩根大通、美銀證券和花旗集團牽頭的一組承銷商發行，其他幾家金融機構則以聯席賬面管理人和聯席經理的身份參與。此次發行預計將於2024年2月26日結束。
有用
沒用